Abstract PR015: Discovery of LY4050784 (FHD-909), a selective BRM (SMARCA2) ATPase inhibitor for the treatment of BRG1(SMARCA4) mutant cancersJanice Y. Lee, Kevin Wilson, Robert S. Flack et al.|Molecular Cancer Therapeutics|2024Cited by 4
Abstract 3230: Discovery of selective BRM (SMARCA2) ATPase inhibitors for the treatment of BRG1 (SMARCA4) mutant cancersJanice Y. Lee, Kevin Wilson, Nathan A. Brooks et al.|Cancer Research|2024Cited by 2
Abstract 3779: LY4050784, a selective inhibitor of SMARCA2, demonstrates synergistic activity in combinations with pembrolizumab or KRAS inhibitorsNathan A. Brooks, Laurie A. LeBrun, Shuang Chen et al.|Cancer Research|2025Cited by 0